INVA | Ticker Profile - Titan Protect

INVA

Innoviva, Inc.

Healthcare · Biotechnology · NMS

$22.52

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.6B

Total market value of the company

Trailing P/E

3.54

Very cheap relative to earnings

Forward P/E

10.01

Based on estimated future earnings — lower means cheaper

Rev Growth

+10.6%

Year-over-year revenue change

Profit Margin

119.9%

How much profit the company keeps from each dollar of revenue

ROE

50.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$39.00

+73% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 4 analysts covering this stock

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

https://www.inva.com

Country: United States Employees: 159 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.870

Good returns relative to risk taken

Kelly Fraction

0.0555

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.832

Acceptable balance between returns and drawdown risk

Annual Return

19.6%

Historical annualised return based on price data

Max Drawdown

-23.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

118

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.38

Very low correlation to market moves

52W High

$25.15

10% below the year high

52W Low

$16.52

36% above the year low

Avg Volume

710,391

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.7%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$6.26

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.70

Heavy leverage — higher financial risk if revenues decline

Current Ratio

21.13

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

19.27

Like current ratio but excludes inventory — stricter test

Gross Margin

74.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

40.1%

Profit from core operations before interest and tax

Free Cash Flow

$105M

Positive — the business generates more cash than it spends

Revenue (TTM)

$421M

Total revenue over the last 12 months

Net Income

$504M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$46.00

Target Median

$39.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go